Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab

Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab

Combination CTLA-4 (ipilimumab) and PD-1 (nivolumab) checkpoint inhibition (dual-ICI) improves survival in patients with advanced melanoma. However, many patients also experience immune-related adverse events (irAE) that require systemic treatment with corticosteroids. Corticosteroids dampen the ant...

Full description

Saved in:
Bibliographic Details
Main Authors: Hifaa Al Remawi, Maria Lindén, Zhiyuan Zhao, Ankur Pandita, Anna Rudin, Lars Ny, Sara Bjursten, Max Levin
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:OncoImmunology
Subjects:
CTLA-4 inhibitor
immune-related adverse events
melanoma
PD-1 inhibitor
survival
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2543510
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2025.2543510

Similar Items